PAPA JOSEPH C — SEC Form 4 filings
SEC reporting owner CIK 1242215. 16 Form 4 filings on record with FilingPulse; latest filed 2026-07-01.
Transaction summary — filings shown
Covers all 16 filings on record, filed 2024-03-15 to 2026-07-01. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 60,000 shares, $349,800 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 20.
- Largest priced transaction: purchase of 60,000 shares @ $5.83 ($349,800) in Emergent BioSolutions Inc., filed 2025-05-15.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | President and CEO, Director | 6 | 1 leg · 60,000 sh · $349,800 | — | 8 |
| Candel Therapeutics, Inc. (CADL) | Director | 6 | — | — | 6 |
| Milestone Pharmaceuticals Inc. (MIST) | Director | 4 | — | — | 6 |
Form 4 filings — PAPA JOSEPH C
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-01 | 4 | Candel Therapeutics, Inc. (CADL) | Grant/award (A): 1,331 (derivative) @ $8.64 | EDGAR |
| 2026-06-24 | 4 | Candel Therapeutics, Inc. (CADL) | Grant/award (A): 32,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Milestone Pharmaceuticals Inc. (MIST) | Grant/award (A): 77,000 (derivative) @ $0 | EDGAR |
| 2026-05-01 | 4 | Emergent BioSolutions Inc. (EBS) | Grant/award (A): 187,708 @ $0 | EDGAR |
| 2026-04-02 | 4 | Candel Therapeutics, Inc. (CADL) | Grant/award (A): 2,795 (derivative) @ $4.11 | EDGAR |
| 2026-03-05 | 4 | Emergent BioSolutions Inc. (EBS) | Tax withholding (F): 37,055 @ $8.44 · Grant/award (A): 252,194 (derivative) @ $0 | EDGAR |
| 2025-07-15 | 4 | Milestone Pharmaceuticals Inc. (MIST) | Grant/award (A): 100,000 · Grant/award (A): 100,000 (derivative) · Grant/award (A): 100,000 (derivative) | EDGAR |
| 2025-06-26 | 4 | Candel Therapeutics, Inc. (CADL) | Grant/award (A): 64,239 @ $4.67 | EDGAR |
| 2025-06-18 | 4 | Candel Therapeutics, Inc. (CADL) | Grant/award (A): 14,240 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Milestone Pharmaceuticals Inc. (MIST) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2025-05-15 | 4 | Emergent BioSolutions Inc. (EBS) | Purchase (P): 60,000 @ $5.83 | EDGAR |
| 2025-03-12 | 4 | Emergent BioSolutions Inc. (EBS) | Grant/award (A): 250,000 (derivative) @ $0 · Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2025-03-10 | 4 | Emergent BioSolutions Inc. (EBS) | Grant/award (A): 282,500 @ $0 · Grant/award (A): 282,500 (derivative) @ $0 | EDGAR |
| 2024-09-05 | 4 | Milestone Pharmaceuticals Inc. (MIST) | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2024-06-27 | 4 | Candel Therapeutics, Inc. (CADL) | Grant/award (A): 14,240 (derivative) @ $0 | EDGAR |
| 2024-03-15 | 4 | Emergent BioSolutions Inc. (EBS) | Grant/award (A): 750,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1242215 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →